Savant Capital LLC Makes New $89,000 Investment in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

Savant Capital LLC acquired a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,083 shares of the company’s stock, valued at approximately $89,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Telemark Asset Management LLC purchased a new position in shares of Terns Pharmaceuticals during the 3rd quarter valued at approximately $2,502,000. Charles Schwab Investment Management Inc. lifted its position in shares of Terns Pharmaceuticals by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 154,714 shares of the company’s stock valued at $1,290,000 after buying an additional 1,994 shares in the last quarter. Quest Partners LLC purchased a new position in shares of Terns Pharmaceuticals during the 3rd quarter valued at approximately $872,000. Bellevue Group AG purchased a new position in shares of Terns Pharmaceuticals during the 3rd quarter valued at approximately $8,691,000. Finally, Parkman Healthcare Partners LLC lifted its position in shares of Terns Pharmaceuticals by 39.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 545,751 shares of the company’s stock valued at $4,552,000 after buying an additional 155,481 shares in the last quarter. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 4,481 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $5.71, for a total value of $25,586.51. Following the completion of the sale, the insider now directly owns 54,269 shares of the company’s stock, valued at $309,875.99. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Mark J. Vignola sold 8,129 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $5.72, for a total value of $46,497.88. Following the completion of the sale, the chief financial officer now directly owns 83,811 shares of the company’s stock, valued at $479,398.92. This trade represents a 8.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders bought 18,210 shares of company stock valued at $124,571 and sold 36,669 shares valued at $211,040. 15.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

TERN has been the topic of a number of recent analyst reports. JMP Securities reiterated a “market outperform” rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a research report on Wednesday, December 4th. Oppenheimer increased their target price on Terns Pharmaceuticals from $17.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, December 4th. Finally, HC Wainwright reissued a “neutral” rating and issued a $7.50 price objective on shares of Terns Pharmaceuticals in a research note on Wednesday, December 4th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Terns Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $18.30.

Terns Pharmaceuticals Stock Performance

NASDAQ TERN opened at $4.19 on Thursday. The business has a fifty day moving average price of $5.06 and a 200 day moving average price of $6.65. Terns Pharmaceuticals, Inc. has a one year low of $4.01 and a one year high of $11.40. The company has a market cap of $355.90 million, a P/E ratio of -3.55 and a beta of -0.34.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.